ArticleCase reports in hematology2026
Diagnostic Ambiguity in BCR-ABL1-Positive MPAL in a Resource-Limited Setting: A Case Report.
Article in Case reports in hematology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Mixed phenotype acute leukemia (MPAL) is a rare hematologic malignancy characterized by the presence of both myeloid and lymphoid lineage markers, posing significant diagnostic and therapeutic challenges. The presence of BCR-ABL1 further complicates classification and management, as it carries important prognostic and therapeutic implications. We report a case of BCR-ABL1-positive MPAL diagnosed through integrated morphological, immunophenotypic, and cytogenetic evaluation. The case highlights key diagnostic pitfalls and underscores the importance of comprehensive immunophenotyping and molecular testing to avoid misclassification as acute myeloid leukemia or acute lymphoblastic leukemia. Recognition of this entity is critical for appropriate therapeutic decision-making, including the use of tyrosine kinase inhibitors. This report emphasizes the need for heightened awareness of MPAL with BCR-ABL1, representing a form of high-risk acute leukemia with significant therapeutic implications, particularly in resource-limited settings where diagnostic constraints may delay optimal management.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.